Pharma channel feed – Endpoints News

Pharma channel feed

Merck pulls the trigger on a new West Coast R&D campus in the heart of a mega-hub

9 years ago

Star-crossed AstraZeneca strikes a drug discovery deal with upstart Bicycle

9 years ago

21st Century Cures Act supporters crush meager House opposition, head to a final showdown in the Senate

9 years ago

In Lechleiter's final days, Eli Lilly flags upcoming job cuts in the wake of a PhIII implosion

9 years ago

Stubborn Actelion CEO Clozel spurs shift in buyout talks, but J&J counters with a raised bid -- reports

9 years ago

House lines up biotech lollipops as support grows for an epic 21st Century Cures Act

9 years ago

Will J&J come up with a big enough treasure trove to win an Actelion buyout?

9 years ago

Novartis swoops in to bag Selexys and its sickle cell drug in $665M deal

9 years ago

Dinner and a biotech chat: Billionaire Patrick Soon-Shiong talks 'innovation' with President-elect Trump

9 years ago

Donald Trump is starting to win over biopharma

9 years ago

Florida's decade-old incentive program to lure research institutions is going belly up

9 years ago

AbbVie, Enanta hep C combo looks stellar in CKD study as rivals hustle along the latest cures

9 years ago

Biotech insider Rich Bagger is out, Gingrich is up in latest reshuffle of Trump’s inner circle

9 years ago

Donald Trump sends a vaguely worded love letter to biopharma as stock rally continues

9 years ago

Bristol-Myers hands over $100M in cash for a new fibrosis drug, beefing up NASH focus

9 years ago

Kite gives itself a little more time to finish FDA application for KTE-C19

9 years ago

Biopharma shares rally as Donald Trump scores a stunning upset

9 years ago

Prop 61 goes down in flames, torching a national drug price control model

9 years ago

Public combat over US drug prices centers on Prop 61 as rhetoric heats up to fever pitch

9 years ago

In a squeaker, FDA AdComm votes for an OK of Cempra’s antibiotic

9 years ago

Clinton’s chief strategist urged tough drug stance that aimed straight for the "cost pain point”

9 years ago

FDA officials: There was “no scientific basis” for Duchenne drug OK as Sarepta complained of “dire financial” condition

9 years ago

On the ropes, Infinity gets a deal for duvelisib, with $0 up front as PI3k flounders

9 years ago

Fast biotech: Gilead hands $200M to computational wiz Nimbus as it speeds into PhII NASH trial

9 years ago

First page Previous page 334 335 336337338 339 340 Next page Last page